J&J sews up 5 years of coronavirus vaccine supply in $480M-plus deal with Emergent Regeneron kicks off prevention trial for COVID-19 antibody cocktail Senate bill aims to preserve 340B eligibility for hospitals affected by COVID-19 pandemic Sanofi, GlaxoSmithKline near $625M COVID-19 vaccine supply deal with U.K. government: report To prep for a complicated flu season, FDA greenlights CDC's combined influenza & COVID-19 test Healthcare roundup: AHA, AMA and ANA urge public to wear masks Biopharma roundup: Zydus Cadila scores OK to run Mexican trials on anemia med in COVID-19 Moderna shares hit by COVID-19 vax trial delay report, but biotech says July start still on track Lessons from China: Agency execs discuss impact of COVID-19 pandemic lockdown and its aftermath on pharma Primary care doctors say they are not ready for next COVID-19 surge Sanofi, Regeneron shut down Kevzara trial in COVID-19 after finding no benefit for ventilated patients Survey: Nearly 1 in 4 assisted living facilities reported at least one case of COVID-19 GSK chief marketing officer talks COVID-19 priority shifts, content creation at Cannes Lions Live Featured Story | By Kyle Blankenship Johnson & Johnson, like all drugmakers in the COVID-19 vaccine race, is hoping to cobble together enough manufacturing capacity to rapidly scale production of its shot hopeful. Now, to the tune of nearly half a billion dollars, J&J is ready to put its money where its mouth is. read more |
| |
|---|
|
| | [Webinar] Zero Deviation Mindset: Achieving Agility in Cell Therapy Supply Chains Tuesday, July 21 | 10am ET / 7am PT Join Thermo Fisher Scientific and Pluristem Therapeutics as we discuss lessons learned in developing the just-in-time supply chain for their phase III hip fracture study, and how these lessons are being used in their current efforts to treat severe COVID-19 cases complicated by Acute Respiratory Distress Syndrome (ARDS) in the United States. Register Now. |
Top Stories By Amirah Al Idrus A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is starting a phase 3 study to see whether the drug can ward off infection in people exposed to COVID-19 patients. To be conducted with the National Institute of Allergy and Infectious Diseases, the trial aims to enroll 2,000 patients through about 100 sites in the U.S. read more By Robert King A new Senate bill seeks to preserve 340B eligibility for hospitals impacted by the COVID-19 pandemic. read more By Angus Liu As COVID-19 vaccines near final stages of testing, governments are also racing against each other, busy securing supply for their own countries. The U.K. government, on the heels of locking up delivery from AstraZeneca, is reportedly ready for more doses from an alliance between Sanofi and GlaxoSmithKline. read more By Conor Hale The FDA issued a new emergency authorization to the Centers for Disease Control and Prevention for a combination influenza and COVID-19 diagnostic test—as the U.S. prepares to enter its annual flu season later this year in the midst of a global pandemic. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner J&J inked a five-year deal with Emergent to make doses of its COVID-19 vaccine. Regeneron and Sanofi axed U.S. trials of Kevzara in COVID-19 after a phase 3 flop. Moderna's shares took a hit after reports surfaced that it might delay its vaccine trial start. Plus, the CDC is rolling out a combo flu/COVID-19 diagnostic. read more By Ben Adams Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report by Stat said the biotech would have to delay the start of its major phase 3 pandemic vaccine trial. read more By Beth Snyder Bulik The COVID-19 pandemic placed China in the spotlight, not only because it had the first cases of the disease but because it had some of the earliest reopenings. It’s an unenviable position, but one that can give insight into the impact on the pharma industry across issues such as digital engagement, healthcare access and communications. read more By Heather Landi As COVID-19 cases continue to rise in parts of the U.S., many primary care practices are not ready to address the current surge or a second wave predicted to come in the fall. read more By Kyle Blankenship In the early days of the COVID-19 pandemic, Sanofi and Regeneron launched an ambitious plan to try out rheumatoid arthritis med Kevzara in desperately ill patients. But after early warning signs, a phase 3 flop has forced the drugmakers to can their U.S. trial. read more By Robert King A new report sought to shed light on the spread of the novel coronavirus in assisted living facilities, which have a fatality rate comparable to nursing homes. read more By Beth Snyder Bulik GlaxoSmithKline had big growth plans for 2020 across its brands—and then the COVID-19 pandemic hit. So the company scrambled to rethink and prioritize “ruthlessly” to find a new way forward. That meant leaning even harder into digital and e-commerce, as well as realigning brand categories to reflect COVID-19 consumer thinking, GSK Chief Marketing Officer Tamara Rogers told attendees of the recent virtual Cannes Lions Live conference. read more |
